Novartis bags elusive US approval for cholesterol drug inclisiranAt its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce Share XNovartis bags elusive US approval for cholesterol drug inclisiranhttps://pharmaphorum.com/news/novartis-bags-elusive-us-approval-for-cholesterol-drug-inclisiran/
Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed Share XCould safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?https://pharmaphorum.com/news/could-safety-scupper-ionis-pfizers-cholesterol-drug-vupanorsen/
Merck’s oral PCSK9 drug matches injectables in early trialsInjectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Share XMerck’s oral PCSK9 drug matches injectables in early trialshttps://pharmaphorum.com/news/mercks-oral-pcsk9-drug-matches-injectables-in-early-trials/
NICE backs NHS use of Novartis’ cholesterol drug LeqvioNovartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help Share XNICE backs NHS use of Novartis’ cholesterol drug Leqviohttps://pharmaphorum.com/news/nice-backs-nhs-use-of-novartis-cholesterol-drug-leqvio/
Novartis eyes New Year verdict from FDA on delayed LeqvioNovartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by Share XNovartis eyes New Year verdict from FDA on delayed Leqviohttps://pharmaphorum.com/news/novartis-eyes-new-year-verdict-from-fda-on-delayed-leqvio/
Novartis tries to rescue stalled inclisiran filing with FDANovartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on Share XNovartis tries to rescue stalled inclisiran filing with FDAhttps://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/
NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
Scotland says no to Daiichi Sankyo’s cholesterol drug NilemdoThe Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, Share XScotland says no to Daiichi Sankyo’s cholesterol drug Nilemdohttps://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/
AstraZeneca sells rights to cholesterol drug Crestor to GrunenthalAstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a Share XAstraZeneca sells rights to cholesterol drug Crestor to Grunenthalhttps://pharmaphorum.com/news/astrazeneca-sells-rights-to-cholesterol-drug-crestor-to-grunenthal/
